These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21599570)

  • 1. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
    Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
    Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
    Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
    Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
    Zateyshchikov DA; Minushkina LO; Brovkin AN; Savel'eva EG; Zateyshchikova AA; Manchaeva BB; Nikitin AG; Sidorenko BA; Nosikov VV
    Fundam Clin Pharmacol; 2007 Aug; 21(4):437-43. PubMed ID: 17635183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
    Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
    Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.
    Si D; Wang J; Xu Y; Chen X; Zhang M; Zhou H
    J Cardiovasc Pharmacol; 2014 Oct; 64(4):306-9. PubMed ID: 25291495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
    Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
    J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
    Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
    Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
    Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
    Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
    Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
    Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
    Miki S; Masumura H; Kaifu Y; Yuasa S
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
    Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
    Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of carvedilol in older and younger patients.
    Morgan T; Anderson A; Cripps J; Adam W
    J Hum Hypertens; 1990 Dec; 4(6):709-15. PubMed ID: 2096213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
    Chan SW; Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
    Rau T; Düngen HD; Edelmann F; Waagstein F; Lainščak M; Dimković S; Apostolović S; Nešković AN; Haverkamp W; Gelbrich G; Eschenhagen T
    Clin Pharmacol Ther; 2012 Jul; 92(1):21-8. PubMed ID: 22617224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.